Profile picture

Assistant Professor Valery Ionin

Saint Petersburg First Pavlov State Medical University, Saint Petersburg (Russian Federation)
Follow
Logo ESC

Contributor content

Cardiotrophin-1 and components of metabolic syndrome: what is the role in the development of atrial fibrillation?
Presentation
Cardiotrophin-1 and components of metabolic syndrome: what is the role in the development of atrial fibrillation?
Profibrogenic biomarkers and severity of left atrial fibrosis in patients with atrial fibrillation and metabolic syndrome: is it possible to predict the effectiveness of therapy?
Presentation
Profibrogenic biomarkers and severity of left atrial fibrosis in patients with atrial fibrillation and metabolic syndrome: is it possible to predict the effectiveness of therapy?
Galectin-3 as a risk factor recurrence of atrial fibrillation in patients with metabolic syndrome
Presentation
Galectin-3 as a risk factor recurrence of atrial fibrillation in patients with metabolic syndrome
Epicardial adipose tissue and transforming growth factor-beta1 - risk factors of atrial fibrillation in patients with metabolic syndrome.
Presentation
Epicardial adipose tissue and transforming growth factor-beta1 - risk factors of atrial fibrillation in patients with metabolic syndrome.
Left atrium fibrosis, epicardial fat and galectin-3 in patients with atrial fibrillation and metabolic syndrome
Presentation
Left atrium fibrosis, epicardial fat and galectin-3 in patients with atrial fibrillation and metabolic syndrome
C(-915)G polymorphism gene of transforming growth factor 1 in patients with metabolic syndrome and atrial fibrillation
Presentation
C(-915)G polymorphism gene of transforming growth factor 1 in patients with metabolic syndrome and atrial fibrillation
Epicardial fat and effectiveness of catheter radiofrequency ablation in patients with atrial fibrillation and metabolic syndrome
Presentation
Epicardial fat and effectiveness of catheter radiofrequency ablation in patients with atrial fibrillation and metabolic syndrome
Can we predict the effect of antiarrhythmic pharmacotherapy in atrial fibrillation and metabolic syndrome patients: focus on galectin-3
Presentation
Can we predict the effect of antiarrhythmic pharmacotherapy in atrial fibrillation and metabolic syndrome patients: focus on galectin-3

ESC 365 is supported by